Oral vs. Injectable Wegovy (Semaglutide): Comparing the Pill, Pen, and HD Dose

For most of its time on the market, Wegovy (semaglutide) meant one regimen: a once-weekly subcutaneous injection titrated to 2.4 mg. Until late 2025, when the FDA approved a once-daily oral tablet, followed by approval of a higher-dose 7.2 mg injection — Wegovy HD — in March 2026. Your patients now have both a needle-free option and a higher-dose injectable to choose from, all under one brand.

This guide compares the oral and injectable forms across the variables that drive prescribing: approved indications, dosing and titration, administration, and efficacy.

Indications

All three forms are approved for weight loss as adjuncts to a reduced-calorie diet and increased physical activity, but their labels diverge.

The traditional 2.4 mg injection is approved for: 

• Weight management in adults (obesity, or overweight with at least one weight-related comorbidity) and in adolescents ages 12 and older with obesity

• MACE risk reduction in adults with established cardiovascular disease who are either obese or overweight

• Noncirrhotic MASH (formerly NASH) with moderate-to-advanced fibrosis in adults

The 25 mg oral tablet is approved for:

• Chronic weight management in adults only

• MACE risk reduction in adults only

Wegovy HD is approved for:

• Chronic weight management in adults only 

Wegovy HD functions as a weight-reduction step-up for adults who have reached the 2.4 mg dose and still need additional weight reduction.

Here’s a quick comparison of the doses and indications.

Dosing

The dosing frequency and titration schedules vary between Wegovy formulations. But both forms start low and step up slowly to limit gastrointestinal (GI) side effects.

The oral tablet is taken once daily, with titration recommended every 30 days.

Injectable doses are given once weekly with titration every 4 weeks.

Here’s how the dosing schedules compare:

Wegovy HD step-up: For adults who tolerate the 2.4 mg injection for at least 4 weeks and need additional weight reduction, the dose may be increased to a maximum of 7.2 mg once weekly (this is known as Wegovy HD). HD is a maintenance step-up, not a starting dose.

Administration

Oral tablet: Gut absorption is critical to oral semaglutide’s efficacy. Oral semaglutide bioavailability is under 1%, versus roughly 89% for the subcutaneous form, so the timing rules are strict. Counsel patients to take one tablet each day in the following manner:

• First thing in the morning on an empty stomach

• With no more than 4 oz of plain water

• Swallow it whole (no splitting, crushing, or chewing)

• Wait at least 30 minutes before any food, other beverages, or other oral medications

Injection: Patients should inject subcutaneously into the abdomen, thigh, or upper arm on the same day each week at any time of day, with or without food. Injection sites should be rotated.

Missed doses: For the injection, give a missed dose as soon as possible, as long as the next one is more than 2 days away; otherwise skip it. Two or more consecutive missed injections may warrant re-titration, depending on the patient. For the tablet, skip the missed dose and resume the next day.

Compared efficacy

Oral tablet: In a 64-week, placebo-controlled trial of 307 adults with obesity (or overweight plus ≥1 comorbidity), mean weight loss with the 25 mg tablet was 16.6% versus roughly 2% to 3% with placebo. About 1 in 3 patients lost 20% or more of their body weight.

Injection 2.4 mg and HD 7.2 mg: In a 72-week trial of 1,407 adults with obesity, mean weight loss was 20.7% with HD 7.2 mg and 17.5% with 2.4 mg. Placebo was about 2% to 4%. About 1 in 3 patients on 7.2 mg lost 25% or more.

Safety and tolerability

The safety profile is largely a class effect and is broadly consistent across formulations. The most common adverse reactions (≥5%) are GI-related — nausea, diarrhea, vomiting, constipation, and abdominal pain — along with headache, fatigue, and dizziness.

At 7.2 mg, side effects are more frequently reported. But generally, side effects were self-limited or resolved with dose reduction.

Boxed warning and contraindications: Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent data. It’s contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Key warnings:

• Pancreatitis and gallbladder disease (cholelithiasis, cholecystitis — partly driven by the rapid weight loss itself)

• Hypoglycemia, typically only when combined with insulin or a sulfonylurea

• Acute kidney injury from volume depletion

• Severe GI effects (avoid in patients with a history of gastroparesis)

• Potential for fetal harm (advise discontinuation at least 2 months before a planned pregnancy due to long half-life)

Ways to save on Wegovy

Wegovy is available only as a brand-name medication. GoodRx coupons and manufacturer copay savings cards can help make a prescription more affordable.

• Save with GoodRx. New GoodRx users can pay an introductory price for the first two fills of $199 per month for the injection and $149 per month for the pill (only available for certain doses). For future fills and for other Wegovy doses, it’s $349 per month for the injection and $299 per month for the pill. Subscribers to GoodRx for Weight Loss can also access FDA-approved brand-name GLP-1 medications.

• Save with a copay card. Those with commercial insurance can pay as little as $25 per month for Wegovy injections or tablets with the manufacturer’s copay card.

How to choose

The starting decision is usually between the 25 mg tablet and the 2.4 mg injection. Wegovy HD is a later step, not an entry point. A few factors tend to drive the choice:

Why trust our experts?

Written by:

Farzon A. Nahvi, MD

Farzon Nahvi, MD, is an emergency medicine physician and author of “Code Gray: Death, Life, and Uncertainty in the ER.” He works at Concord Hospital in Concord, New Hampshire, and teaches at the Geisel School of Medicine at Dartmouth.

Edited by:

Mandy Armitage, MD

Mandy Armitage, MD, has combined clinical medicine with her passion for education and content development for many years. She is co-executive director at Nonclinical Physicians Network and has served as medical director for the health technology companies HealthLoop (now Get Well) and Doximity.

Reviewed by:

Farah Naz Khan, MD

Farah Naz Khan, MD, is a board-certified physician at the UW Medicine Diabetes Institute and a clinical assistant professor of metabolism, endocrinology, and nutrition at the University of Washington.

Our editorial standards

Meet our experts